<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head>

<meta charset="utf-8">
<meta name="generator" content="quarto-1.5.57">

<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">


<title>Detailed summary – &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exeter Oncology Model: Renal Cell Carcinoma edition</title>
<style>
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
div.columns{display: flex; gap: min(4vw, 1.5em);}
div.column{flex: auto; overflow-x: auto;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
ul.task-list li input[type="checkbox"] {
  width: 0.8em;
  margin: 0 0.8em 0.2em -1em; /* quarto-specific, see https://github.com/quarto-dev/quarto-cli/issues/4556 */ 
  vertical-align: middle;
}
/* CSS for citations */
div.csl-bib-body { }
div.csl-entry {
  clear: both;
  margin-bottom: 0em;
}
.hanging-indent div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}</style>


<script src="../site_libs/quarto-nav/quarto-nav.js"></script>
<script src="../site_libs/quarto-nav/headroom.min.js"></script>
<script src="../site_libs/clipboard/clipboard.min.js"></script>
<script src="../site_libs/quarto-search/autocomplete.umd.js"></script>
<script src="../site_libs/quarto-search/fuse.min.js"></script>
<script src="../site_libs/quarto-search/quarto-search.js"></script>
<meta name="quarto:offset" content="../">
<script src="../site_libs/quarto-html/quarto.js"></script>
<script src="../site_libs/quarto-html/popper.min.js"></script>
<script src="../site_libs/quarto-html/tippy.umd.min.js"></script>
<script src="../site_libs/quarto-html/anchor.min.js"></script>
<link href="../site_libs/quarto-html/tippy.css" rel="stylesheet">
<link href="../site_libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<script src="../site_libs/bootstrap/bootstrap.min.js"></script>
<link href="../site_libs/bootstrap/bootstrap-icons.css" rel="stylesheet">
<link href="../site_libs/bootstrap/bootstrap.min.css" rel="stylesheet" id="quarto-bootstrap" data-mode="light">
<script src="../site_libs/quarto-contrib/glightbox/glightbox.min.js"></script>
<link href="../site_libs/quarto-contrib/glightbox/glightbox.min.css" rel="stylesheet">
<link href="../site_libs/quarto-contrib/glightbox/lightbox.css" rel="stylesheet">
<script id="quarto-search-options" type="application/json">{
  "location": "navbar",
  "copy-button": false,
  "collapse-after": 3,
  "panel-placement": "end",
  "type": "overlay",
  "limit": 50,
  "keyboard-shortcut": [
    "f",
    "/",
    "s"
  ],
  "show-item-context": false,
  "language": {
    "search-no-results-text": "No results",
    "search-matching-documents-text": "matching documents",
    "search-copy-link-title": "Copy link to search",
    "search-hide-matches-text": "Hide additional matches",
    "search-more-match-text": "more match in this document",
    "search-more-matches-text": "more matches in this document",
    "search-clear-button-title": "Clear",
    "search-text-placeholder": "",
    "search-detached-cancel-button-title": "Cancel",
    "search-submit-button-title": "Submit",
    "search-label": "Search"
  }
}</script>


<link rel="stylesheet" href="../styles.css">
</head>

<body class="nav-sidebar docked nav-fixed">

<div id="quarto-search-results"></div>
  <header id="quarto-header" class="headroom fixed-top">
    <nav class="navbar navbar-expand " data-bs-theme="dark">
      <div class="navbar-container container-fluid">
      <div class="navbar-brand-container mx-auto">
    <a href="../index.html" class="navbar-brand navbar-brand-logo">
    <img src="../images/exeter_pentag_small.png" alt="Exeter PenTAG" class="navbar-logo">
    </a>
    <a class="navbar-brand" href="../index.html">
    <span class="navbar-title">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exeter Oncology Model: Renal Cell Carcinoma edition</span>
    </a>
  </div>
          <ul class="navbar-nav navbar-nav-scroll ms-auto">
  <li class="nav-item compact">
    <a class="nav-link" href="https://github.com/pythonhealthdatascience/stars-eom-rcc/"> <i class="bi bi-github" role="img">
</i> 
<span class="menu-text"></span></a>
  </li>  
</ul>
          <div class="quarto-navbar-tools">
</div>
            <div id="quarto-search" class="" title="Search"></div>
      </div> <!-- /container-fluid -->
    </nav>
  <nav class="quarto-secondary-nav">
    <div class="container-fluid d-flex">
      <button type="button" class="quarto-btn-toggle btn" data-bs-toggle="collapse" role="button" data-bs-target=".quarto-sidebar-collapse-item" aria-controls="quarto-sidebar" aria-expanded="false" aria-label="Toggle sidebar navigation" onclick="if (window.quartoToggleHeadroom) { window.quartoToggleHeadroom(); }">
        <i class="bi bi-layout-text-sidebar-reverse"></i>
      </button>
        <nav class="quarto-page-breadcrumbs" aria-label="breadcrumb"><ol class="breadcrumb"><li class="breadcrumb-item"><a href="../pages/model_overview.html">Model overview</a></li><li class="breadcrumb-item"><a href="../pages/model_overview.html">Detailed summary</a></li></ol></nav>
        <a class="flex-grow-1" role="navigation" data-bs-toggle="collapse" data-bs-target=".quarto-sidebar-collapse-item" aria-controls="quarto-sidebar" aria-expanded="false" aria-label="Toggle sidebar navigation" onclick="if (window.quartoToggleHeadroom) { window.quartoToggleHeadroom(); }">      
        </a>
    </div>
  </nav>
</header>
<!-- content -->
<div id="quarto-content" class="quarto-container page-columns page-rows-contents page-layout-article page-navbar">
<!-- sidebar -->
  <nav id="quarto-sidebar" class="sidebar collapse collapse-horizontal quarto-sidebar-collapse-item sidebar-navigation docked overflow-auto">
    <div class="sidebar-menu-container"> 
    <ul class="list-unstyled mt-1">
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="../index.html" class="sidebar-item-text sidebar-link">
 <span class="menu-text">Home</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="../pages/acronyms.html" class="sidebar-item-text sidebar-link">
 <span class="menu-text">Acryonyms</span></a>
  </div>
</li>
        <li class="sidebar-item sidebar-item-section">
      <div class="sidebar-item-container"> 
            <a class="sidebar-item-text sidebar-link text-start" data-bs-toggle="collapse" data-bs-target="#quarto-sidebar-section-1" role="navigation" aria-expanded="true">
 <span class="menu-text">Context</span></a>
          <a class="sidebar-item-toggle text-start" data-bs-toggle="collapse" data-bs-target="#quarto-sidebar-section-1" role="navigation" aria-expanded="true" aria-label="Toggle section">
            <i class="bi bi-chevron-right ms-2"></i>
          </a> 
      </div>
      <ul id="quarto-sidebar-section-1" class="collapse list-unstyled sidebar-section depth1 show">  
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="../pages/appraisals.html" class="sidebar-item-text sidebar-link">
 <span class="menu-text">NICE appraisals</span></a>
  </div>
</li>
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="../pages/publication.html" class="sidebar-item-text sidebar-link">
 <span class="menu-text">List of articles and reports</span></a>
  </div>
</li>
      </ul>
  </li>
        <li class="sidebar-item sidebar-item-section">
      <div class="sidebar-item-container"> 
            <a class="sidebar-item-text sidebar-link text-start" data-bs-toggle="collapse" data-bs-target="#quarto-sidebar-section-2" role="navigation" aria-expanded="true">
 <span class="menu-text">Model overview</span></a>
          <a class="sidebar-item-toggle text-start" data-bs-toggle="collapse" data-bs-target="#quarto-sidebar-section-2" role="navigation" aria-expanded="true" aria-label="Toggle section">
            <i class="bi bi-chevron-right ms-2"></i>
          </a> 
      </div>
      <ul id="quarto-sidebar-section-2" class="collapse list-unstyled sidebar-section depth1 show">  
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="../pages/model_overview.html" class="sidebar-item-text sidebar-link active">
 <span class="menu-text">Detailed summary</span></a>
  </div>
</li>
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="../pages/plain_english.html" class="sidebar-item-text sidebar-link">
 <span class="menu-text">Plain english summary</span></a>
  </div>
</li>
      </ul>
  </li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="../pages/installation.html" class="sidebar-item-text sidebar-link">
 <span class="menu-text">Installation</span></a>
  </div>
</li>
        <li class="sidebar-item sidebar-item-section">
      <div class="sidebar-item-container"> 
            <a class="sidebar-item-text sidebar-link text-start" data-bs-toggle="collapse" data-bs-target="#quarto-sidebar-section-3" role="navigation" aria-expanded="true">
 <span class="menu-text">Code walkthrough</span></a>
          <a class="sidebar-item-toggle text-start" data-bs-toggle="collapse" data-bs-target="#quarto-sidebar-section-3" role="navigation" aria-expanded="true" aria-label="Toggle section">
            <i class="bi bi-chevron-right ms-2"></i>
          </a> 
      </div>
      <ul id="quarto-sidebar-section-3" class="collapse list-unstyled sidebar-section depth1 show">  
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="../pages/walkthrough_preface.html" class="sidebar-item-text sidebar-link">
 <span class="menu-text">Preface</span></a>
  </div>
</li>
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="../pages/input_data.html" class="sidebar-item-text sidebar-link">
 <span class="menu-text">Input data</span></a>
  </div>
</li>
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="../pages/walkthrough/code1_setup.html" class="sidebar-item-text sidebar-link">
 <span class="menu-text">Set-up</span></a>
  </div>
</li>
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="../pages/walkthrough/code2_extrapolate.html" class="sidebar-item-text sidebar-link">
 <span class="menu-text">Extrapolate real-world evidence</span></a>
  </div>
</li>
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="../pages/walkthrough/code3_hr.html" class="sidebar-item-text sidebar-link">
 <span class="menu-text">Apply hazard ratios to reference curves</span></a>
  </div>
</li>
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="../pages/walkthrough/code4_prep.html" class="sidebar-item-text sidebar-link">
 <span class="menu-text">Prepare other data</span></a>
  </div>
</li>
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="../pages/walkthrough/code5_model.html" class="sidebar-item-text sidebar-link">
 <span class="menu-text">Economic modelling</span></a>
  </div>
</li>
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="../pages/report.html" class="sidebar-item-text sidebar-link">
 <span class="menu-text">Report</span></a>
  </div>
</li>
      </ul>
  </li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="../pages/probabilistic.html" class="sidebar-item-text sidebar-link">
 <span class="menu-text">Probabilistic analysis</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="../pages/scenarios.html" class="sidebar-item-text sidebar-link">
 <span class="menu-text">Scenario analysis</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="../pages/license.html" class="sidebar-item-text sidebar-link">
 <span class="menu-text">License</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="../pages/citation.html" class="sidebar-item-text sidebar-link">
 <span class="menu-text">Citation</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="../pages/changelog.html" class="sidebar-item-text sidebar-link">
 <span class="menu-text">Changelog</span></a>
  </div>
</li>
    </ul>
    </div>
</nav>
<div id="quarto-sidebar-glass" class="quarto-sidebar-collapse-item" data-bs-toggle="collapse" data-bs-target=".quarto-sidebar-collapse-item"></div>
<!-- margin-sidebar -->
    <div id="quarto-margin-sidebar" class="sidebar margin-sidebar">
        <nav id="TOC" role="doc-toc" class="toc-active">
    <h2 id="toc-title">On this page</h2>
   
  <ul>
  <li><a href="#background" id="toc-background" class="nav-link active" data-scroll-target="#background">Background</a>
  <ul class="collapse">
  <li><a href="#renal-cell-carnioma-stages-and-risk-groups" id="toc-renal-cell-carnioma-stages-and-risk-groups" class="nav-link" data-scroll-target="#renal-cell-carnioma-stages-and-risk-groups">Renal cell carnioma stages and risk groups</a></li>
  <li><a href="#focus-of-the-appraisal" id="toc-focus-of-the-appraisal" class="nav-link" data-scroll-target="#focus-of-the-appraisal">Focus of the appraisal</a></li>
  </ul></li>
  <li><a href="#summary-diagram" id="toc-summary-diagram" class="nav-link" data-scroll-target="#summary-diagram">Summary diagram</a></li>
  <li><a href="#stage-1.-estimating-the-relative-efficacy-of-each-treatment" id="toc-stage-1.-estimating-the-relative-efficacy-of-each-treatment" class="nav-link" data-scroll-target="#stage-1.-estimating-the-relative-efficacy-of-each-treatment">Stage 1. Estimating the relative efficacy of each treatment</a>
  <ul class="collapse">
  <li><a href="#identification-of-randomised-controlled-trials" id="toc-identification-of-randomised-controlled-trials" class="nav-link" data-scroll-target="#identification-of-randomised-controlled-trials">Identification of randomised controlled trials</a></li>
  <li><a href="#network-meta-analysis" id="toc-network-meta-analysis" class="nav-link" data-scroll-target="#network-meta-analysis">Network meta-analysis</a></li>
  </ul></li>
  <li><a href="#stage-2.-extrapolating-survival-curves-from-real-world-evidence" id="toc-stage-2.-extrapolating-survival-curves-from-real-world-evidence" class="nav-link" data-scroll-target="#stage-2.-extrapolating-survival-curves-from-real-world-evidence">Stage 2. Extrapolating survival curves from real-world evidence</a>
  <ul class="collapse">
  <li><a href="#identification-of-rwe" id="toc-identification-of-rwe" class="nav-link" data-scroll-target="#identification-of-rwe">Identification of RWE</a></li>
  <li><a href="#extrapolation-of-rwe" id="toc-extrapolation-of-rwe" class="nav-link" data-scroll-target="#extrapolation-of-rwe">Extrapolation of RWE</a></li>
  </ul></li>
  <li><a href="#stage-3.-applying-nma-hazard-ratios-to-rwe-reference-curves" id="toc-stage-3.-applying-nma-hazard-ratios-to-rwe-reference-curves" class="nav-link" data-scroll-target="#stage-3.-applying-nma-hazard-ratios-to-rwe-reference-curves">Stage 3. Applying NMA hazard ratios to RWE reference curves</a>
  <ul class="collapse">
  <li><a href="#reference-curves" id="toc-reference-curves" class="nav-link" data-scroll-target="#reference-curves">Reference curves</a></li>
  <li><a href="#applying-the-hazard-ratios-to-the-reference-curves" id="toc-applying-the-hazard-ratios-to-the-reference-curves" class="nav-link" data-scroll-target="#applying-the-hazard-ratios-to-the-reference-curves">Applying the hazard ratios to the reference curves</a></li>
  </ul></li>
  <li><a href="#stage-4.-modifications-to-the-extrapolations" id="toc-stage-4.-modifications-to-the-extrapolations" class="nav-link" data-scroll-target="#stage-4.-modifications-to-the-extrapolations">Stage 4. Modifications to the extrapolations</a>
  <ul class="collapse">
  <li><a href="#treatment-effect-waning" id="toc-treatment-effect-waning" class="nav-link" data-scroll-target="#treatment-effect-waning">Treatment effect waning</a></li>
  <li><a href="#general-population-mortality" id="toc-general-population-mortality" class="nav-link" data-scroll-target="#general-population-mortality">General population mortality</a></li>
  <li><a href="#overlapping-curves" id="toc-overlapping-curves" class="nav-link" data-scroll-target="#overlapping-curves">Overlapping curves</a></li>
  </ul></li>
  <li><a href="#stage-5.-preparation-of-other-data-for-the-economic-models" id="toc-stage-5.-preparation-of-other-data-for-the-economic-models" class="nav-link" data-scroll-target="#stage-5.-preparation-of-other-data-for-the-economic-models">Stage 5. Preparation of other data for the economic models</a>
  <ul class="collapse">
  <li><a href="#adverse-events" id="toc-adverse-events" class="nav-link" data-scroll-target="#adverse-events">Adverse events</a></li>
  <li><a href="#utility-values" id="toc-utility-values" class="nav-link" data-scroll-target="#utility-values">Utility values</a></li>
  <li><a href="#resource-use-and-costs" id="toc-resource-use-and-costs" class="nav-link" data-scroll-target="#resource-use-and-costs">Resource use and costs</a></li>
  <li><a href="#treatment-sequences" id="toc-treatment-sequences" class="nav-link" data-scroll-target="#treatment-sequences">Treatment sequences</a></li>
  <li><a href="#proportion-of-people-receiving-each-treatment-in-practice" id="toc-proportion-of-people-receiving-each-treatment-in-practice" class="nav-link" data-scroll-target="#proportion-of-people-receiving-each-treatment-in-practice">Proportion of people receiving each treatment in practice</a></li>
  </ul></li>
  <li><a href="#stage-6.-economic-models" id="toc-stage-6.-economic-models" class="nav-link" data-scroll-target="#stage-6.-economic-models">Stage 6. Economic models</a>
  <ul class="collapse">
  <li><a href="#model-diagram" id="toc-model-diagram" class="nav-link" data-scroll-target="#model-diagram">Model diagram</a></li>
  <li><a href="#methodology" id="toc-methodology" class="nav-link" data-scroll-target="#methodology">Methodology</a></li>
  </ul></li>
  <li><a href="#stage-7.-processing-model-results" id="toc-stage-7.-processing-model-results" class="nav-link" data-scroll-target="#stage-7.-processing-model-results">Stage 7. Processing model results</a>
  <ul class="collapse">
  <li><a href="#severity-modifier" id="toc-severity-modifier" class="nav-link" data-scroll-target="#severity-modifier">Severity modifier</a></li>
  </ul></li>
  </ul>
<div class="toc-actions"><ul><li><a href="https://github.com/pythonhealthdatascience/stars-eom-rcc/edit/main/pages/model_overview.qmd" class="toc-action"><i class="bi bi-github"></i>Edit this page</a></li><li><a href="https://github.com/pythonhealthdatascience/stars-eom-rcc/issues/new" class="toc-action"><i class="bi empty"></i>Report an issue</a></li></ul></div></nav>
    </div>
<!-- main -->
<main class="content" id="quarto-document-content">

<header id="title-block-header" class="quarto-title-block default"><nav class="quarto-page-breadcrumbs quarto-title-breadcrumbs d-none d-lg-block" aria-label="breadcrumb"><ol class="breadcrumb"><li class="breadcrumb-item"><a href="../pages/model_overview.html">Model overview</a></li><li class="breadcrumb-item"><a href="../pages/model_overview.html">Detailed summary</a></li></ol></nav>
<div class="quarto-title">
<h1 class="title">Detailed summary</h1>
</div>



<div class="quarto-title-meta">

    
  
    
  </div>
  


</header>


<p>This repository contains code to support appraisal of the cost-effectiveness of treatments in advanced renal cell carcinoma. It is currently applied to an appraisal of cabozantinib and nivolumab. This application and an overview of the analysis and modelling steps performed are described below.</p>
<section id="background" class="level2">
<h2 class="anchored" data-anchor-id="background">Background</h2>
<section id="renal-cell-carnioma-stages-and-risk-groups" class="level3">
<h3 class="anchored" data-anchor-id="renal-cell-carnioma-stages-and-risk-groups">Renal cell carnioma stages and risk groups</h3>
<p><strong>Renal cell carcinoma (RCC)</strong> is a type of <strong>kidney cancer</strong>. It is the most common type, accounting for over 80% of cases. The treatment strategy depends on RCC’s location and stage. The stages of RCC can be defined as:</p>
<table class="caption-top table">
<colgroup>
<col style="width: 33%">
<col style="width: 33%">
<col style="width: 33%">
</colgroup>
<thead>
<tr class="header">
<th>Stage 1 and 2</th>
<th>Stage 3</th>
<th>Stage 4</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Cancer is only in the kidney</td>
<td>Cancer may have spread to nearby lymph nodes</td>
<td>Cancer has metastasised, meaning it has spread to other areas of the body; Also known as <strong>advanced RCC (aRCC)</strong></td>
</tr>
</tbody>
</table>
<p>People with aRCC who have not yet received systemic treatments (therapies that target cancer cells throughout the body) are classified as either being <strong>favourable-risk</strong> RCC or <strong>intermediate- and poor-risk</strong> RCC. These categories are defined in the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria. They are established based on time from diagnosis, the patient’s ability to perform daily tasks, and some laboratory measurements. In the UK, most RCC patients are classified as intermediate or poor risk. Risk status is associated with clinical outcomes (for example, mortality rates). It is used to help guide decisions on which treatments to use.</p>
<p>For more information, see section 2.2 “Epidemiology” and 2.3.1 “Risk Status” in the Assessment Report. <span class="citation" data-cites="lee_treatments_2023-1">[<a href="#ref-lee_treatments_2023-1" role="doc-biblioref">1</a>]</span></p>
</section>
<section id="focus-of-the-appraisal" class="level3">
<h3 class="anchored" data-anchor-id="focus-of-the-appraisal">Focus of the appraisal</h3>
<p>The analysis in this repository is related to the NICE appraisal TA964 <span class="citation" data-cites="national_institute_for_health_and_care_excellence_nice_cabozantinib_2024">[<a href="#ref-national_institute_for_health_and_care_excellence_nice_cabozantinib_2024" role="doc-biblioref">2</a>]</span> which assesses the clinical- and cost-effectiveness of <strong>cabozantinib with nivolumab</strong> as a <strong>first-line therapy</strong> for patients with <strong>aRCC</strong>.</p>
<p>This treatment is a combination of:</p>
<ul>
<li>Cabozantinib - oral, 40mg daily</li>
<li>Nivolumab - intravenous, 240mg every 2 weeks or 480mg every 4 weeks</li>
</ul>
<p>It is a first-line (1L) systemic therapy, meaning it is for previously untreated patients. They may then have up to 3 more treatments (referred to as second-line (2L), third-line (3L) and fourth-line (4L) therapies), or at any point, may instead transition to receiving best-supportive care (BSC).</p>
<p>The appraisal compares this treatment <strong>against other 1L treatments</strong>. When modelling this, it includes a simulation of the subsequent treatments that people might receive after each.</p>
<p>For more information, see section 3.2 “Interventions” and 3.3 “The RCC treatment pathway” in the Assessment Report. <span class="citation" data-cites="lee_treatments_2023-1">[<a href="#ref-lee_treatments_2023-1" role="doc-biblioref">1</a>]</span></p>
</section>
</section>
<section id="summary-diagram" class="level2">
<h2 class="anchored" data-anchor-id="summary-diagram">Summary diagram</h2>
<div class="quarto-figure quarto-figure-center">
<figure class="figure">
<p><a href="../images/detailed_overview_vertical.drawio.png" class="lightbox" data-gallery="quarto-lightbox-gallery-1" title="Overview of analysis performed for this appraisal."><img src="../images/detailed_overview_vertical.drawio.png" class="img-fluid figure-img" alt="Overview of analysis performed for this appraisal."></a></p>
<figcaption>Overview of analysis performed for this appraisal.</figcaption>
</figure>
</div>
</section>
<section id="stage-1.-estimating-the-relative-efficacy-of-each-treatment" class="level2">
<h2 class="anchored" data-anchor-id="stage-1.-estimating-the-relative-efficacy-of-each-treatment">Stage 1. Estimating the relative efficacy of each treatment</h2>
<div class="quarto-figure quarto-figure-center">
<figure class="figure">
<p><a href="../images/detailed_stage1.drawio.png" class="lightbox" data-gallery="quarto-lightbox-gallery-2" title="Excerpt from overview diagram for Stage 1"><img src="../images/detailed_stage1.drawio.png" class="img-fluid figure-img" alt="Excerpt from overview diagram for Stage 1"></a></p>
<figcaption>Excerpt from overview diagram for Stage 1</figcaption>
</figure>
</div>
<section id="identification-of-randomised-controlled-trials" class="level3">
<h3 class="anchored" data-anchor-id="identification-of-randomised-controlled-trials">Identification of randomised controlled trials</h3>
<p>A systematic review was conducted to identified <strong>randomised controlled trials (RCTs)</strong> of patients with aRCC who received any of the treatments under comparison - namely: cabozantinib plus nivolumab; pazopanib; tivozanib; sunitinib; cabozantinib; nivolumab plus ipilimumab; pembrolizumab and lenvatinib; axitinib; lenvatinib plus everolimus; everolimus; nivolumab; avelumab plus axitinib</p>
<p>The studies had to report at least one of the outcomes of interest:</p>
<ul>
<li><strong>Overall survival (OS)</strong> - “time from randomisation to death” <span class="citation" data-cites="delgado_clinical_2021">[<a href="#ref-delgado_clinical_2021" role="doc-biblioref">3</a>]</span></li>
<li><strong>Progression-free survival (PFS)</strong> - “time from randomisation until first evidence of disease progression or death” <span class="citation" data-cites="delgado_clinical_2021">[<a href="#ref-delgado_clinical_2021" role="doc-biblioref">3</a>]</span></li>
<li><strong>Time to next treatment (TTNT)</strong> - “time from initiating treatment to initiating the next line of therapy” <span class="citation" data-cites="delgado_clinical_2021">[<a href="#ref-delgado_clinical_2021" role="doc-biblioref">3</a>]</span></li>
<li><strong>Time on treatment</strong> - similar to TTNT, but excluding time off treatment between lines of therapy</li>
<li><strong>Response rates</strong> (also known as objective response rate) - the proportion of people with partial response (decrease in tumour size) or complete response (disappearance of all signs of cancer) <span class="citation" data-cites="nih_national_cancer_institute_nci_nci_nodate">[<a href="#ref-nih_national_cancer_institute_nci_nci_nodate" role="doc-biblioref">4</a>]</span></li>
<li><strong>Duration of response</strong> - “time from randomisation to disease progression or death in patients who achieve complete or partial response” <span class="citation" data-cites="delgado_clinical_2021">[<a href="#ref-delgado_clinical_2021" role="doc-biblioref">3</a>]</span></li>
<li><strong>Adverse events (AEs) of treatment</strong> - “undesired effect” of treatment <span class="citation" data-cites="nih_national_cancer_institute_nci_nci_nodate">[<a href="#ref-nih_national_cancer_institute_nci_nci_nodate" role="doc-biblioref">4</a>]</span></li>
<li><strong>Health-related quality of life (HRQoL)</strong> - “the impact a medical condition and/or treatment has on a patient’s functioning and well-being” <span class="citation" data-cites="york_health_economics_consortium_quality_2016">[<a href="#ref-york_health_economics_consortium_quality_2016" role="doc-biblioref">5</a>]</span></li>
</ul>
<p>The review identified 24 RCTs to include (plus an additional 6, but these were ongoing). All 24 studies recorded OS, PFS, response rate and adverse events, whilst other outcomes were more sparsely recorded.</p>
<p>For more information, see section “3.1.1 Identification of systematic literature reviews and randomised controlled trials” and “Table 11 Outcomes reported by RCTs included in the review” in the Assessment Report <span class="citation" data-cites="lee_treatments_2023-1">[<a href="#ref-lee_treatments_2023-1" role="doc-biblioref">1</a>]</span> and section 1.8 “Literature review approach” in the Pathway Model Report. <span class="citation" data-cites="national_institute_for_health_and_care_excellence_nice_renal_2024">[<a href="#ref-national_institute_for_health_and_care_excellence_nice_renal_2024" role="doc-biblioref">6</a>]</span></p>
</section>
<section id="network-meta-analysis" class="level3">
<h3 class="anchored" data-anchor-id="network-meta-analysis">Network meta-analysis</h3>
<p>The identified trials do not all include the same treatments, with each comparing different therapies head-to-head. To illustrate this, below are 1L network diagrams for PFS and OS, as based on Figures 16 and 17 in the Assessment Report. <span class="citation" data-cites="lee_treatments_2023-1">[<a href="#ref-lee_treatments_2023-1" role="doc-biblioref">1</a>]</span> These show which treatments were directly compared head-to-head: each circle represents a treatment, and each line represents a clinical trial.</p>
<div class="quarto-figure quarto-figure-center">
<figure class="figure">
<p><a href="../images/network_diagram.drawio.png" class="lightbox" data-gallery="quarto-lightbox-gallery-3" title="1L network diagrams for PFS and OS, as adapted from the Assessment Report. Abbreviations: ave, avelumab; axi, axitinib; cabo, cabozantinib; ipi, ipilimumab; lenv, lenvatinib; nivo, nivolumab; pazo, pazopanib; pem, pembrolizumab; sora, sorafenib; suni, sunitinib; tivo, tivozanib."><img src="../images/network_diagram.drawio.png" class="img-fluid figure-img" alt="1L network diagrams for PFS and OS, as adapted from the Assessment Report. Abbreviations: ave, avelumab; axi, axitinib; cabo, cabozantinib; ipi, ipilimumab; lenv, lenvatinib; nivo, nivolumab; pazo, pazopanib; pem, pembrolizumab; sora, sorafenib; suni, sunitinib; tivo, tivozanib."></a></p>
<figcaption>1L network diagrams for PFS and OS, as adapted from the Assessment Report. Abbreviations: ave, avelumab; axi, axitinib; cabo, cabozantinib; ipi, ipilimumab; lenv, lenvatinib; nivo, nivolumab; pazo, pazopanib; pem, pembrolizumab; sora, sorafenib; suni, sunitinib; tivo, tivozanib.</figcaption>
</figure>
</div>
<p>For our economic model, we need to understand the clinical effectiveness of each treatment for each outcome, relative to the other treatments. This is measured using <strong>hazard ratios (HR)</strong>, which are “a measure of how often a particular event happens in one group compared to how often it happens in another group, over time”. <span class="citation" data-cites="nih_national_cancer_institute_nci_nci_nodate">[<a href="#ref-nih_national_cancer_institute_nci_nci_nodate" role="doc-biblioref">4</a>]</span></p>
<p>In order to estimate the comparative effectiveness of interventions that may not have been compared head-to-head in a randomised trial, <strong>network meta-analyses (NMA)</strong> were performed. Two types of NMA were used:</p>
<ul>
<li><strong>Proportional hazards NMA (PH NMA)</strong> which returns a single hazard ratio for each comparison, as it “assumes the relative effects of each treatment… remain constant over time”</li>
<li><strong>Fractional polynomial NMA (FP NMA)</strong> which returns a list of time-varying hazard ratios for each comparison, as it “allows the relative effects to change over time” <span class="citation" data-cites="national_institute_for_health_and_care_excellence_nice_renal_2024">[<a href="#ref-national_institute_for_health_and_care_excellence_nice_renal_2024" role="doc-biblioref">6</a>]</span></li>
</ul>
<p>For each RCT, requests were made to the company that owned each trial’s data, asking for grouped survival data (in time intervals of 1 or 4 weeks), for used in the NMAs. If this was not received, then the published curves were digitised to estimate the grouped survival data.</p>
<p>NMA were performed for:</p>
<ul>
<li><strong>OS and PFS</strong> in the all-risk group, favourable-risk and intermediate- and poor-risk subgroups</li>
<li><strong>Safety</strong> for the all-risk group</li>
</ul>
<p>PH NMA and FP NMA were both conducted, but the chosen models used were:</p>
<ul>
<li><strong>FP NMA</strong> for 1L efficacy - as the “flexible time-varying hazard ratios… provided a better, more plausible fit to observed short-term data” <span class="citation" data-cites="national_institute_for_health_and_care_excellence_nice_renal_2024">[<a href="#ref-national_institute_for_health_and_care_excellence_nice_renal_2024" role="doc-biblioref">6</a>]</span> and as the proportional hazards was violated for some 1L treatments. However, PH NMA was used for pembrolizumab plus lenvatinib, as FP NMA produced implausible results.</li>
<li><strong>PH NMA</strong> was used for 2L and 3L efficacy due to the “sparsity of the available network and extreme results within the fitted models” <span class="citation" data-cites="lee_treatments_2023-1">[<a href="#ref-lee_treatments_2023-1" role="doc-biblioref">1</a>]</span></li>
<li>4L efficacy was based on 3L outcomes, applying the hazard ratio for the difference between pooled 3L and 4L outcomes</li>
</ul>
<p>For more information, see section 1.16 “Relative effectiveness” in the Pathway Model Report <span class="citation" data-cites="national_institute_for_health_and_care_excellence_nice_renal_2024">[<a href="#ref-national_institute_for_health_and_care_excellence_nice_renal_2024" role="doc-biblioref">6</a>]</span> and 4.3.5.2 “Calculation of relative treatment effectiveness” in the Assessment Report. <span class="citation" data-cites="lee_treatments_2023-1">[<a href="#ref-lee_treatments_2023-1" role="doc-biblioref">1</a>]</span></p>
</section>
</section>
<section id="stage-2.-extrapolating-survival-curves-from-real-world-evidence" class="level2">
<h2 class="anchored" data-anchor-id="stage-2.-extrapolating-survival-curves-from-real-world-evidence">Stage 2. Extrapolating survival curves from real-world evidence</h2>
<div class="quarto-figure quarto-figure-center">
<figure class="figure">
<p><a href="../images/detailed_stage2.drawio.png" class="lightbox" data-gallery="quarto-lightbox-gallery-4" title="Excerpt from overview diagram for Stage 2"><img src="../images/detailed_stage2.drawio.png" class="img-fluid figure-img" alt="Excerpt from overview diagram for Stage 2"></a></p>
<figcaption>Excerpt from overview diagram for Stage 2</figcaption>
</figure>
</div>
<section id="identification-of-rwe" class="level3">
<h3 class="anchored" data-anchor-id="identification-of-rwe">Identification of RWE</h3>
<p>A targeted search was conducted to identify RWE (i.e.&nbsp;observational studies describing outcomes in practice, outside of a trial setting). The search was for studies that included patients with aRCC and described at least one of:</p>
<ul>
<li>Treatment pathways</li>
<li>Natural history of disease</li>
<li>Patient characteristics</li>
</ul>
<p>Of the 12 real-world datasets identified, only one was considered to be robust and relevant to the UK. This was Challapalli et al.&nbsp;2022. <span class="citation" data-cites="challapalli_1463p_2022">[<a href="#ref-challapalli_1463p_2022" role="doc-biblioref">7</a>]</span> The owners of this dataset provided access to patient-level data.</p>
<p>For more information, see section 1.12 “Real-world evidence” in the Pathway Model Report <span class="citation" data-cites="national_institute_for_health_and_care_excellence_nice_renal_2024">[<a href="#ref-national_institute_for_health_and_care_excellence_nice_renal_2024" role="doc-biblioref">6</a>]</span> and 3.1.2 “Identification of real-world evidence” in the Assessment Report. <span class="citation" data-cites="lee_treatments_2023-1">[<a href="#ref-lee_treatments_2023-1" role="doc-biblioref">1</a>]</span></p>
</section>
<section id="extrapolation-of-rwe" class="level3">
<h3 class="anchored" data-anchor-id="extrapolation-of-rwe">Extrapolation of RWE</h3>
<p>The OS, PFS, time to discontinuation (TTD), time to progression (TTP) and post-progression survival (PPS) survival curves from Challapalli et al.&nbsp;2022 <span class="citation" data-cites="challapalli_1463p_2022">[<a href="#ref-challapalli_1463p_2022" role="doc-biblioref">7</a>]</span> were extrapolated so that they covered the <strong>time horizon</strong> of the economic model, which was <strong>40 years</strong>. Extrapolation was conducted using <strong>survival analysis</strong> (with a <strong>partitioned survival model</strong>).</p>
<p>For more information, see section 4.3.5.1 “Extrapolation of survival curves” in the Assessment Report <span class="citation" data-cites="lee_treatments_2023-1">[<a href="#ref-lee_treatments_2023-1" role="doc-biblioref">1</a>]</span> and section 1.13 “Baseline risk” in the Pathway Model Report. <span class="citation" data-cites="national_institute_for_health_and_care_excellence_nice_renal_2024">[<a href="#ref-national_institute_for_health_and_care_excellence_nice_renal_2024" role="doc-biblioref">6</a>]</span></p>
</section>
</section>
<section id="stage-3.-applying-nma-hazard-ratios-to-rwe-reference-curves" class="level2">
<h2 class="anchored" data-anchor-id="stage-3.-applying-nma-hazard-ratios-to-rwe-reference-curves">Stage 3. Applying NMA hazard ratios to RWE reference curves</h2>
<div class="quarto-figure quarto-figure-center">
<figure class="figure">
<p><a href="../images/detailed_stage34.drawio.png" class="lightbox" data-gallery="quarto-lightbox-gallery-5" title="Excerpt from overview diagram for Stage 3 and 4"><img src="../images/detailed_stage34.drawio.png" class="img-fluid figure-img" alt="Excerpt from overview diagram for Stage 3 and 4"></a></p>
<figcaption>Excerpt from overview diagram for Stage 3 and 4</figcaption>
</figure>
</div>
<section id="reference-curves" class="level3">
<h3 class="anchored" data-anchor-id="reference-curves">Reference curves</h3>
<p>For 1L, the reference treatment used was <strong>sunitinib</strong> as it:</p>
<ul>
<li>It is used in UK practice for all risk groups</li>
<li>It was the most common 1L treatment in the RWE</li>
<li>Was the comparator for the most of the RCTs (see the network diagram above)</li>
</ul>
<p>For 2L and 3L, the reference treatment used was <strong>cabozantinib</strong> as:</p>
<ul>
<li>It was the most common 2L and 3L treatment in the RWE</li>
<li>“Data were mature compared to other treatments” <span class="citation" data-cites="lee_treatments_2023-1">[<a href="#ref-lee_treatments_2023-1" role="doc-biblioref">1</a>]</span></li>
</ul>
<p>The reference treatment was based on RWE as per recommendations from the NICE manual and other recent appraisals.</p>
<p>For more information, see section 4.3.5 “Treatment effectiveness and extrapolation” in the Assessment Report <span class="citation" data-cites="lee_treatments_2023-1">[<a href="#ref-lee_treatments_2023-1" role="doc-biblioref">1</a>]</span> and sections 1.13 “Baseline risk” and 1.14 “Appropriateness” in the Pathway Model Report. <span class="citation" data-cites="national_institute_for_health_and_care_excellence_nice_renal_2024">[<a href="#ref-national_institute_for_health_and_care_excellence_nice_renal_2024" role="doc-biblioref">6</a>]</span></p>
</section>
<section id="applying-the-hazard-ratios-to-the-reference-curves" class="level3">
<h3 class="anchored" data-anchor-id="applying-the-hazard-ratios-to-the-reference-curves">Applying the hazard ratios to the reference curves</h3>
<p>The effectiveness of 1L sunitinib and 2L cabozantinib is provided by the RWE reference curves. For all other treatments, the effectiveness is calculated by applying the NMA HRs to the reference curves.</p>
<p>The source of the HRs for each treatment, line and outcome were as follows:</p>
<ul>
<li><strong>PFS and OS from the NMA</strong> - FP NMA for 1L (with exception of pembrolizumab plus lenvatinib) and PH NMA for 2L and 3L</li>
<li>Assume <strong>1L pazopanib and tivozanib</strong> effectiveness are the same as sunitinib (as not available in NMA)</li>
<li>Assume <strong>2L/3L sunitinib and pazopanib</strong> effectiveness are the same as tizovanib (as not available in NMA)</li>
<li>Assume <strong>1L TTD and TTP</strong> are the same as PFS</li>
<li>Assume <strong>2L/3L TTP</strong> is the same as PFS, but for <strong>TTD</strong> apply a hazard ratio to the PFS, as calculated from the 1L treatments</li>
<li>Calculate <strong>4L outcomes</strong> by applying hazard ratio on 3L outcomes</li>
</ul>
<p>In the code, the nested list containing the HRs and survival times for each treatment is referred to as a <strong>relative efficacy network</strong>, and when the hazard ratios are applied to the reference curve, this was described as <strong>propagating</strong> the network.</p>
<p>For more information, see section 4.3.5.2 “Calculation of relative treatment effectiveness” in the Assessment Report <span class="citation" data-cites="lee_treatments_2023-1">[<a href="#ref-lee_treatments_2023-1" role="doc-biblioref">1</a>]</span> and section 1.16 “Relative effectiveness” in the Pathway Model Report. <span class="citation" data-cites="national_institute_for_health_and_care_excellence_nice_renal_2024">[<a href="#ref-national_institute_for_health_and_care_excellence_nice_renal_2024" role="doc-biblioref">6</a>]</span></p>
</section>
</section>
<section id="stage-4.-modifications-to-the-extrapolations" class="level2">
<h2 class="anchored" data-anchor-id="stage-4.-modifications-to-the-extrapolations">Stage 4. Modifications to the extrapolations</h2>
<section id="treatment-effect-waning" class="level3">
<h3 class="anchored" data-anchor-id="treatment-effect-waning">Treatment effect waning</h3>
<p>Treatment effect waning is when the hazard/survival for a treatment converges to the hazard/survival of the comparator. This was implemented at 5 years for 1L combination therapies that included an immuno-oncology (IO) treatment and tyrosine kinase inhibitor (TKI) (for example, axitinib and avelumab). It was set at 5 years as that is when people stop having that therapy in clinical practice.</p>
<p>For more information, see section 1.22 “Treatment effect waning” in the Pathway Model Report <span class="citation" data-cites="national_institute_for_health_and_care_excellence_nice_renal_2024">[<a href="#ref-national_institute_for_health_and_care_excellence_nice_renal_2024" role="doc-biblioref">6</a>]</span> and 4.3.5.3 “Treatment effectiveness waning” in the Assessment Report. <span class="citation" data-cites="lee_treatments_2023-1">[<a href="#ref-lee_treatments_2023-1" role="doc-biblioref">1</a>]</span></p>
</section>
<section id="general-population-mortality" class="level3">
<h3 class="anchored" data-anchor-id="general-population-mortality">General population mortality</h3>
<p>If aRCC patients were projected to live longer than the general population, this was corrected (hence, ensuring the aRCC OS never exceeds the general population). General population mortality was based on an age and sex matched-profile (against the 1L all risk population) using data from the Office for National Statistics (ONS).</p>
<p>For more information, see section 4.3.5.4 “Accounting for general population mortality” in the Assessment Report. <span class="citation" data-cites="lee_treatments_2023-1">[<a href="#ref-lee_treatments_2023-1" role="doc-biblioref">1</a>]</span></p>
</section>
<section id="overlapping-curves" class="level3">
<h3 class="anchored" data-anchor-id="overlapping-curves">Overlapping curves</h3>
<p>A known limitation of partitioned survival analysis (which was used to extrapolate the RWE) is that it can produce curves where PFS lies above OS (which is impossible in real-life). Hence, in cases where this occurs, it was adjusted so that PFS &lt;= OS (and also, PFS &lt;= TTP).</p>
<p>For more information, see section 4.3.5.5 “Adjustment for curves crossing” in the Assessment Report. <span class="citation" data-cites="lee_treatments_2023-1">[<a href="#ref-lee_treatments_2023-1" role="doc-biblioref">1</a>]</span></p>
</section>
</section>
<section id="stage-5.-preparation-of-other-data-for-the-economic-models" class="level2">
<h2 class="anchored" data-anchor-id="stage-5.-preparation-of-other-data-for-the-economic-models">Stage 5. Preparation of other data for the economic models</h2>
<div class="quarto-figure quarto-figure-center">
<figure class="figure">
<p><a href="../images/detailed_stage567.drawio.png" class="lightbox" data-gallery="quarto-lightbox-gallery-6" title="Excerpt from overview diagram for Stage 5, 6 and 7"><img src="../images/detailed_stage567.drawio.png" class="img-fluid figure-img" alt="Excerpt from overview diagram for Stage 5, 6 and 7"></a></p>
<figcaption>Excerpt from overview diagram for Stage 5, 6 and 7</figcaption>
</figure>
</div>
<section id="adverse-events" class="level3">
<h3 class="anchored" data-anchor-id="adverse-events">Adverse events</h3>
<p>As for the effectiveness outcomes from the NMA, the hazard ratios for grade 3+ adverse events calculated in the NMA were applied to reference curves. For all grade adverse events, hazard ratios from an NMA in a cochrane review were used. The reference curves (i.e.&nbsp;the baseline adverse event risk in the model) were:</p>
<ul>
<li>1L - sunitib from Checkmate 9ER RCT</li>
<li>2L and 3L - everolimus from CheckMate 025 RCT</li>
</ul>
<p>This is with the exception of cabozantinib plus nivolumab, whose rates were based directly on Checkmate 9ER RCT data.</p>
<p>For more information, see section 1.24 “Adverse events” in the Pathway Model Report <span class="citation" data-cites="national_institute_for_health_and_care_excellence_nice_renal_2024">[<a href="#ref-national_institute_for_health_and_care_excellence_nice_renal_2024" role="doc-biblioref">6</a>]</span> and 4.3.6 “Adverse events” in the Assessment Report. <span class="citation" data-cites="lee_treatments_2023-1">[<a href="#ref-lee_treatments_2023-1" role="doc-biblioref">1</a>]</span></p>
</section>
<section id="utility-values" class="level3">
<h3 class="anchored" data-anchor-id="utility-values">Utility values</h3>
<p>For <strong>each line of treatment</strong>, there was a:</p>
<ul>
<li>Utility value for patients who were <strong>progression free</strong></li>
<li>Utility value for patients with <strong>progressed disease</strong></li>
<li>Utility value for <strong>BSC</strong></li>
</ul>
<p>The values were sourced from prior NICE technology appraisals - TA645 for 1L and then adjustment to that based on TA498 for 2L to 4L. These were identified through a systematic search for published cost-effectiveness studies.</p>
<p>Utility values were adjusted for age and sex using Ara and Brazier et al.&nbsp;2010 <span class="citation" data-cites="ara_populating_2010">[<a href="#ref-ara_populating_2010" role="doc-biblioref">8</a>]</span> / 2011 <span class="citation" data-cites="ara_using_2011">[<a href="#ref-ara_using_2011" role="doc-biblioref">9</a>]</span> and the Health Survey England (HSE) 2014 dataset.</p>
<p>For more information, see sections 1.25 “Health-related quality of life” and 1.26 “Source of utility values” in the Pathway Model Report <span class="citation" data-cites="national_institute_for_health_and_care_excellence_nice_renal_2024">[<a href="#ref-national_institute_for_health_and_care_excellence_nice_renal_2024" role="doc-biblioref">6</a>]</span> and sections 4.1 “Published cost-effectiveness studies” and 4.3.7 “Utility values” in the Assessment Report. <span class="citation" data-cites="lee_treatments_2023-1">[<a href="#ref-lee_treatments_2023-1" role="doc-biblioref">1</a>]</span></p>
</section>
<section id="resource-use-and-costs" class="level3">
<h3 class="anchored" data-anchor-id="resource-use-and-costs">Resource use and costs</h3>
<p>Similar to the utility values, resource use was based on prior NICE technology appraisals, whilst costs were based on NHS reference costs and costs from the Personal Social Services Research Unit. These include estimates of resource use and costs for:</p>
<ul>
<li><strong>Disease management/health state</strong> (i.e.&nbsp;consultant and specialist nurse visits, CT scans, blood tests, pain medication)</li>
<li><strong>End of life</strong> (i.e.&nbsp;GP appointments, district nursing care, social care, hospital care)</li>
<li><strong>Drug and administration</strong> (i.e.&nbsp;costs of each drug)</li>
<li><strong>Adverse events</strong> (e.g.&nbsp;Grade 1/2 events like diarrehoea or fatigue, and Grade 3+ events like anaemia, hypertension and nausea)</li>
<li><strong>Subsequent treatment</strong> (i.e.&nbsp;radiotherapy, surgery)</li>
</ul>
<p>For more information, see section 4.3.8 “Resource use and costs” in the Assessment Report <span class="citation" data-cites="lee_treatments_2023-1">[<a href="#ref-lee_treatments_2023-1" role="doc-biblioref">1</a>]</span> and sections 1.27 “Resource use” and 1.28 “Relative dose intensity” in the Pathway Model Report. <span class="citation" data-cites="national_institute_for_health_and_care_excellence_nice_renal_2024">[<a href="#ref-national_institute_for_health_and_care_excellence_nice_renal_2024" role="doc-biblioref">6</a>]</span></p>
</section>
<section id="treatment-sequences" class="level3">
<h3 class="anchored" data-anchor-id="treatment-sequences">Treatment sequences</h3>
<p>A list of possible treatment sequences was defined based on rules which were established based on clinical advice and routine commissioning rules. These rules are listed in section 4.3.5.6 “Calculation of final outcomes by first line treatment” in the Assessment Report. <span class="citation" data-cites="lee_treatments_2023-1">[<a href="#ref-lee_treatments_2023-1" role="doc-biblioref">1</a>]</span> Some examples include:</p>
<ul>
<li>Nivolumab plus ipilimumab 1L is only available to intermediate/poor risk patients</li>
<li>Some therapies can’t be used if an immuno-oncology treatment was used in the past year</li>
<li>Lenvatinib plus everolimus can only be used after a prior anti-vascular endothelial growth factor (anti-VEGF) treatment</li>
</ul>
</section>
<section id="proportion-of-people-receiving-each-treatment-in-practice" class="level3">
<h3 class="anchored" data-anchor-id="proportion-of-people-receiving-each-treatment-in-practice">Proportion of people receiving each treatment in practice</h3>
<p>The proportion of people receiving each treatment in the model is based on the observed practices in the RWE.</p>
<p>For more information, see section 4.3.1.8 “EAG model structure” in the Assessment Report <span class="citation" data-cites="lee_treatments_2023-1">[<a href="#ref-lee_treatments_2023-1" role="doc-biblioref">1</a>]</span> and section 1.23 “Sequencing subsequent treatments” in the Pathway Model Report. <span class="citation" data-cites="national_institute_for_health_and_care_excellence_nice_renal_2024">[<a href="#ref-national_institute_for_health_and_care_excellence_nice_renal_2024" role="doc-biblioref">6</a>]</span></p>
</section>
</section>
<section id="stage-6.-economic-models" class="level2">
<h2 class="anchored" data-anchor-id="stage-6.-economic-models">Stage 6. Economic models</h2>
<section id="model-diagram" class="level3">
<h3 class="anchored" data-anchor-id="model-diagram">Model diagram</h3>
<p>The economic model is designed to model up to four lines of treatment before best supportive care. A diagram of the model is provided below. There are ten possible health states:</p>
<ul>
<li>First line (1L) off or on treatment</li>
<li>Second line (2L) off or on treatment</li>
<li>Third line (3L) off or on treatment</li>
<li>Fourth line (4L) off or on treatment</li>
<li>Best supportive case (BSC)</li>
<li>Death</li>
</ul>
<p>Transition between lines of treatment can be defined by either progression-free survival (PFS) or time to next treatment (TTNT).</p>
<!-- This is based on the diagrams in the excel input sheet, and in the renal cell carcinoma (RCC) pathway model report, but created in draw.io -->
<div class="quarto-figure quarto-figure-center">
<figure class="figure">
<p><a href="../images/eomrcc_transitions.drawio.png" class="lightbox" data-gallery="quarto-lightbox-gallery-7" title="Structure of the model and transition between health states"><img src="../images/eomrcc_transitions.drawio.png" class="img-fluid figure-img" alt="Structure of the model and transition between health states"></a></p>
<figcaption>Structure of the model and transition between health states</figcaption>
</figure>
</div>
<p>For more information, see section 4.3.1.8 “EAG model structure” in the Assessment Report <span class="citation" data-cites="lee_treatments_2023-1">[<a href="#ref-lee_treatments_2023-1" role="doc-biblioref">1</a>]</span> and 1.6 “Economic model structure” in the Pathway Model Report. <span class="citation" data-cites="national_institute_for_health_and_care_excellence_nice_renal_2024">[<a href="#ref-national_institute_for_health_and_care_excellence_nice_renal_2024" role="doc-biblioref">6</a>]</span></p>
</section>
<section id="methodology" class="level3">
<h3 class="anchored" data-anchor-id="methodology">Methodology</h3>
<p>Two modelling approaches were explored, with the creation of:</p>
<ul>
<li>A <strong>state transition model</strong> (i.e.&nbsp;a <strong>Markov model</strong>)</li>
<li>A <strong>partitioned survival model</strong> (i.e.&nbsp;partitioned surival analysis)</li>
</ul>
<p>The models aimed to estimate the costs and benefits of cabolizumab plus nivolumab, compared against other 1L treatments, whilst also incorporating information on the subsequent treatment pathways. People in the models started on 1L treatment. The models ran with weekly cycles over a 40 year time horizon. Costs and outcomes were <strong>discounted</strong> at a rate of 3.5% per year.</p>
<p>The committee preferred the state transition model as it allowed multiple treatment lines to be modelled in as much detail as possible (with a state transition model being more flexible and able to explore more uncertainties and alternative assumptions).</p>
<p>For more information, see section 1.6 “Economic model structure” in the Pathway Model Report <span class="citation" data-cites="national_institute_for_health_and_care_excellence_nice_renal_2024">[<a href="#ref-national_institute_for_health_and_care_excellence_nice_renal_2024" role="doc-biblioref">6</a>]</span> and 4.3 “EAG economic analysis” in the Assessment Report. <span class="citation" data-cites="lee_treatments_2023-1">[<a href="#ref-lee_treatments_2023-1" role="doc-biblioref">1</a>]</span></p>
</section>
</section>
<section id="stage-7.-processing-model-results" class="level2">
<h2 class="anchored" data-anchor-id="stage-7.-processing-model-results">Stage 7. Processing model results</h2>
<p>The models simulate how a cohort of patients would transition between health states over the time horizon, depending on which treatments they received. It returns the proportion of patients over time in each health state. We then apply:</p>
<ul>
<li><strong>Costs</strong></li>
<li><strong>Utilities</strong>, with <strong>quality-adjusted life years (QALYs)</strong> calculated from multiplying the years in a health state by the utility score</li>
</ul>
<p>An <strong>incremental cost-effectiveness ratio (ICER)</strong> can be calculated from the difference in costs divided by the difference in QALYs, and these can be compared between treatments.</p>
<section id="severity-modifier" class="level3">
<h3 class="anchored" data-anchor-id="severity-modifier">Severity modifier</h3>
<p>A greater weight can be given to QALYs if the treatment is for a condition with a high degree of severity, and this is referred to as a severity modifier. It was implemented for the state transition model, meaning that the results included absolute and proportional shortfall estimates of QALYs. Three methods were explored for calculating the severity modifier.</p>
<p>For more information, see section 1.29 “Severity” in the Pathway Model Report <span class="citation" data-cites="national_institute_for_health_and_care_excellence_nice_renal_2024">[<a href="#ref-national_institute_for_health_and_care_excellence_nice_renal_2024" role="doc-biblioref">6</a>]</span> and 4.3.9 “Severity” in the Assessment Report. <span class="citation" data-cites="lee_treatments_2023-1">[<a href="#ref-lee_treatments_2023-1" role="doc-biblioref">1</a>]</span></p>



</section>
</section>

<div id="quarto-appendix" class="default"><section class="quarto-appendix-contents" role="doc-bibliography" id="quarto-bibliography"><h2 class="anchored quarto-appendix-heading">References</h2><div id="refs" class="references csl-bib-body" data-entry-spacing="0" role="list">
<div id="ref-lee_treatments_2023-1" class="csl-entry" role="listitem">
<div class="csl-left-margin">[1] </div><div class="csl-right-inline">Lee D, Muthukumar M, Lovell A, Farmer C, Burns D, Matthews J, et al. <a href="https://www.nice.org.uk/guidance/ta964/documents/assessment-report">Treatments for renal cell carcinoma [<span>ID6186</span>]: <span>A</span> <span>Pathways</span> <span>Pilot</span> <span>Appraisal</span> <span>Assessment</span> <span>Report</span></a>. Peninsula Technology Assessment Group (PenTAG) 2023.</div>
</div>
<div id="ref-national_institute_for_health_and_care_excellence_nice_cabozantinib_2024" class="csl-entry" role="listitem">
<div class="csl-left-margin">[2] </div><div class="csl-right-inline">National Institute for Health and Care Excellence (NICE). <a href="https://www.nice.org.uk/guidance/ta964">Cabozantinib with nivolumab for untreated advanced renal cell carcinoma. <span>Technology</span> appraisal guidance [<span>TA964</span>]</a> 2024.</div>
</div>
<div id="ref-delgado_clinical_2021" class="csl-entry" role="listitem">
<div class="csl-left-margin">[3] </div><div class="csl-right-inline">Delgado A, Guddati AK. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085844">Clinical endpoints in oncology - a primer</a>. American Journal of Cancer Research 2021;11:1121–31.</div>
</div>
<div id="ref-nih_national_cancer_institute_nci_nci_nodate" class="csl-entry" role="listitem">
<div class="csl-left-margin">[4] </div><div class="csl-right-inline">NIH National Cancer Institute (NCI). <a href="https://www.cancer.gov/publications/dictionaries/cancer-terms"><span>NCI</span> <span>Dictionary</span> of <span>Cancer</span> <span>Terms</span></a> n.d.</div>
</div>
<div id="ref-york_health_economics_consortium_quality_2016" class="csl-entry" role="listitem">
<div class="csl-left-margin">[5] </div><div class="csl-right-inline">York Health Economics Consortium. <a href="https://yhec.co.uk/glossary/quality-of-life/">Quality of <span>Life</span></a>. YHEC 2016.</div>
</div>
<div id="ref-national_institute_for_health_and_care_excellence_nice_renal_2024" class="csl-entry" role="listitem">
<div class="csl-left-margin">[6] </div><div class="csl-right-inline">National Institute for Health and Care Excellence (NICE). <a href="https://www.nice.org.uk/guidance/ta964/resources/renal-cell-carcinoma-pathway-model-report-pdf-17325260829637">Renal cell carcinoma pathway model report. <span>Economic</span> analysis.</a> 2024.</div>
</div>
<div id="ref-challapalli_1463p_2022" class="csl-entry" role="listitem">
<div class="csl-left-margin">[7] </div><div class="csl-right-inline">Challapalli A, Ratnayake G, McGrane J, Frazer R, Gupta S, Parslow DS, et al. <span>1463P</span> <span>Patterns</span> of care and outcomes of metastatic renal cell carcinoma (<span class="nocase">mRCC</span>) patients (pts) with bone metastases (<span>BM</span>): <span>A</span> <span>UK</span> multicenter review. Annals of Oncology 2022;33:S1215. <a href="https://doi.org/10.1016/j.annonc.2022.07.1566">https://doi.org/10.1016/j.annonc.2022.07.1566</a>.</div>
</div>
<div id="ref-ara_populating_2010" class="csl-entry" role="listitem">
<div class="csl-left-margin">[8] </div><div class="csl-right-inline">Ara R, Brazier JE. Populating an <span>Economic</span> <span>Model</span> with <span>Health</span> <span>State</span> <span>Utility</span> <span>Values</span>: <span>Moving</span> toward <span>Better</span> <span>Practice</span>. Value in Health 2010;13:509–18. <a href="https://doi.org/10.1111/j.1524-4733.2010.00700.x">https://doi.org/10.1111/j.1524-4733.2010.00700.x</a>.</div>
</div>
<div id="ref-ara_using_2011" class="csl-entry" role="listitem">
<div class="csl-left-margin">[9] </div><div class="csl-right-inline">Ara R, Brazier JE. Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research 2011;14:539–45. <a href="https://doi.org/10.1016/j.jval.2010.10.029">https://doi.org/10.1016/j.jval.2010.10.029</a>.</div>
</div>
</div></section></div></main> <!-- /main -->
<script id="quarto-html-after-body" type="application/javascript">
window.document.addEventListener("DOMContentLoaded", function (event) {
  const toggleBodyColorMode = (bsSheetEl) => {
    const mode = bsSheetEl.getAttribute("data-mode");
    const bodyEl = window.document.querySelector("body");
    if (mode === "dark") {
      bodyEl.classList.add("quarto-dark");
      bodyEl.classList.remove("quarto-light");
    } else {
      bodyEl.classList.add("quarto-light");
      bodyEl.classList.remove("quarto-dark");
    }
  }
  const toggleBodyColorPrimary = () => {
    const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
    if (bsSheetEl) {
      toggleBodyColorMode(bsSheetEl);
    }
  }
  toggleBodyColorPrimary();  
  const icon = "";
  const anchorJS = new window.AnchorJS();
  anchorJS.options = {
    placement: 'right',
    icon: icon
  };
  anchorJS.add('.anchored');
  const isCodeAnnotation = (el) => {
    for (const clz of el.classList) {
      if (clz.startsWith('code-annotation-')) {                     
        return true;
      }
    }
    return false;
  }
  const onCopySuccess = function(e) {
    // button target
    const button = e.trigger;
    // don't keep focus
    button.blur();
    // flash "checked"
    button.classList.add('code-copy-button-checked');
    var currentTitle = button.getAttribute("title");
    button.setAttribute("title", "Copied!");
    let tooltip;
    if (window.bootstrap) {
      button.setAttribute("data-bs-toggle", "tooltip");
      button.setAttribute("data-bs-placement", "left");
      button.setAttribute("data-bs-title", "Copied!");
      tooltip = new bootstrap.Tooltip(button, 
        { trigger: "manual", 
          customClass: "code-copy-button-tooltip",
          offset: [0, -8]});
      tooltip.show();    
    }
    setTimeout(function() {
      if (tooltip) {
        tooltip.hide();
        button.removeAttribute("data-bs-title");
        button.removeAttribute("data-bs-toggle");
        button.removeAttribute("data-bs-placement");
      }
      button.setAttribute("title", currentTitle);
      button.classList.remove('code-copy-button-checked');
    }, 1000);
    // clear code selection
    e.clearSelection();
  }
  const getTextToCopy = function(trigger) {
      const codeEl = trigger.previousElementSibling.cloneNode(true);
      for (const childEl of codeEl.children) {
        if (isCodeAnnotation(childEl)) {
          childEl.remove();
        }
      }
      return codeEl.innerText;
  }
  const clipboard = new window.ClipboardJS('.code-copy-button:not([data-in-quarto-modal])', {
    text: getTextToCopy
  });
  clipboard.on('success', onCopySuccess);
  if (window.document.getElementById('quarto-embedded-source-code-modal')) {
    // For code content inside modals, clipBoardJS needs to be initialized with a container option
    // TODO: Check when it could be a function (https://github.com/zenorocha/clipboard.js/issues/860)
    const clipboardModal = new window.ClipboardJS('.code-copy-button[data-in-quarto-modal]', {
      text: getTextToCopy,
      container: window.document.getElementById('quarto-embedded-source-code-modal')
    });
    clipboardModal.on('success', onCopySuccess);
  }
    var localhostRegex = new RegExp(/^(?:http|https):\/\/localhost\:?[0-9]*\//);
    var mailtoRegex = new RegExp(/^mailto:/);
      var filterRegex = new RegExp("https:\/\/pythonhealthdatascience\.github\.io\/stars-eom-rcc\/");
    var isInternal = (href) => {
        return filterRegex.test(href) || localhostRegex.test(href) || mailtoRegex.test(href);
    }
    // Inspect non-navigation links and adorn them if external
 	var links = window.document.querySelectorAll('a[href]:not(.nav-link):not(.navbar-brand):not(.toc-action):not(.sidebar-link):not(.sidebar-item-toggle):not(.pagination-link):not(.no-external):not([aria-hidden]):not(.dropdown-item):not(.quarto-navigation-tool):not(.about-link)');
    for (var i=0; i<links.length; i++) {
      const link = links[i];
      if (!isInternal(link.href)) {
        // undo the damage that might have been done by quarto-nav.js in the case of
        // links that we want to consider external
        if (link.dataset.originalHref !== undefined) {
          link.href = link.dataset.originalHref;
        }
      }
    }
  function tippyHover(el, contentFn, onTriggerFn, onUntriggerFn) {
    const config = {
      allowHTML: true,
      maxWidth: 500,
      delay: 100,
      arrow: false,
      appendTo: function(el) {
          return el.parentElement;
      },
      interactive: true,
      interactiveBorder: 10,
      theme: 'quarto',
      placement: 'bottom-start',
    };
    if (contentFn) {
      config.content = contentFn;
    }
    if (onTriggerFn) {
      config.onTrigger = onTriggerFn;
    }
    if (onUntriggerFn) {
      config.onUntrigger = onUntriggerFn;
    }
    window.tippy(el, config); 
  }
  const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
  for (var i=0; i<noterefs.length; i++) {
    const ref = noterefs[i];
    tippyHover(ref, function() {
      // use id or data attribute instead here
      let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
      try { href = new URL(href).hash; } catch {}
      const id = href.replace(/^#\/?/, "");
      const note = window.document.getElementById(id);
      if (note) {
        return note.innerHTML;
      } else {
        return "";
      }
    });
  }
  const xrefs = window.document.querySelectorAll('a.quarto-xref');
  const processXRef = (id, note) => {
    // Strip column container classes
    const stripColumnClz = (el) => {
      el.classList.remove("page-full", "page-columns");
      if (el.children) {
        for (const child of el.children) {
          stripColumnClz(child);
        }
      }
    }
    stripColumnClz(note)
    if (id === null || id.startsWith('sec-')) {
      // Special case sections, only their first couple elements
      const container = document.createElement("div");
      if (note.children && note.children.length > 2) {
        container.appendChild(note.children[0].cloneNode(true));
        for (let i = 1; i < note.children.length; i++) {
          const child = note.children[i];
          if (child.tagName === "P" && child.innerText === "") {
            continue;
          } else {
            container.appendChild(child.cloneNode(true));
            break;
          }
        }
        if (window.Quarto?.typesetMath) {
          window.Quarto.typesetMath(container);
        }
        return container.innerHTML
      } else {
        if (window.Quarto?.typesetMath) {
          window.Quarto.typesetMath(note);
        }
        return note.innerHTML;
      }
    } else {
      // Remove any anchor links if they are present
      const anchorLink = note.querySelector('a.anchorjs-link');
      if (anchorLink) {
        anchorLink.remove();
      }
      if (window.Quarto?.typesetMath) {
        window.Quarto.typesetMath(note);
      }
      // TODO in 1.5, we should make sure this works without a callout special case
      if (note.classList.contains("callout")) {
        return note.outerHTML;
      } else {
        return note.innerHTML;
      }
    }
  }
  for (var i=0; i<xrefs.length; i++) {
    const xref = xrefs[i];
    tippyHover(xref, undefined, function(instance) {
      instance.disable();
      let url = xref.getAttribute('href');
      let hash = undefined; 
      if (url.startsWith('#')) {
        hash = url;
      } else {
        try { hash = new URL(url).hash; } catch {}
      }
      if (hash) {
        const id = hash.replace(/^#\/?/, "");
        const note = window.document.getElementById(id);
        if (note !== null) {
          try {
            const html = processXRef(id, note.cloneNode(true));
            instance.setContent(html);
          } finally {
            instance.enable();
            instance.show();
          }
        } else {
          // See if we can fetch this
          fetch(url.split('#')[0])
          .then(res => res.text())
          .then(html => {
            const parser = new DOMParser();
            const htmlDoc = parser.parseFromString(html, "text/html");
            const note = htmlDoc.getElementById(id);
            if (note !== null) {
              const html = processXRef(id, note);
              instance.setContent(html);
            } 
          }).finally(() => {
            instance.enable();
            instance.show();
          });
        }
      } else {
        // See if we can fetch a full url (with no hash to target)
        // This is a special case and we should probably do some content thinning / targeting
        fetch(url)
        .then(res => res.text())
        .then(html => {
          const parser = new DOMParser();
          const htmlDoc = parser.parseFromString(html, "text/html");
          const note = htmlDoc.querySelector('main.content');
          if (note !== null) {
            // This should only happen for chapter cross references
            // (since there is no id in the URL)
            // remove the first header
            if (note.children.length > 0 && note.children[0].tagName === "HEADER") {
              note.children[0].remove();
            }
            const html = processXRef(null, note);
            instance.setContent(html);
          } 
        }).finally(() => {
          instance.enable();
          instance.show();
        });
      }
    }, function(instance) {
    });
  }
      let selectedAnnoteEl;
      const selectorForAnnotation = ( cell, annotation) => {
        let cellAttr = 'data-code-cell="' + cell + '"';
        let lineAttr = 'data-code-annotation="' +  annotation + '"';
        const selector = 'span[' + cellAttr + '][' + lineAttr + ']';
        return selector;
      }
      const selectCodeLines = (annoteEl) => {
        const doc = window.document;
        const targetCell = annoteEl.getAttribute("data-target-cell");
        const targetAnnotation = annoteEl.getAttribute("data-target-annotation");
        const annoteSpan = window.document.querySelector(selectorForAnnotation(targetCell, targetAnnotation));
        const lines = annoteSpan.getAttribute("data-code-lines").split(",");
        const lineIds = lines.map((line) => {
          return targetCell + "-" + line;
        })
        let top = null;
        let height = null;
        let parent = null;
        if (lineIds.length > 0) {
            //compute the position of the single el (top and bottom and make a div)
            const el = window.document.getElementById(lineIds[0]);
            top = el.offsetTop;
            height = el.offsetHeight;
            parent = el.parentElement.parentElement;
          if (lineIds.length > 1) {
            const lastEl = window.document.getElementById(lineIds[lineIds.length - 1]);
            const bottom = lastEl.offsetTop + lastEl.offsetHeight;
            height = bottom - top;
          }
          if (top !== null && height !== null && parent !== null) {
            // cook up a div (if necessary) and position it 
            let div = window.document.getElementById("code-annotation-line-highlight");
            if (div === null) {
              div = window.document.createElement("div");
              div.setAttribute("id", "code-annotation-line-highlight");
              div.style.position = 'absolute';
              parent.appendChild(div);
            }
            div.style.top = top - 2 + "px";
            div.style.height = height + 4 + "px";
            div.style.left = 0;
            let gutterDiv = window.document.getElementById("code-annotation-line-highlight-gutter");
            if (gutterDiv === null) {
              gutterDiv = window.document.createElement("div");
              gutterDiv.setAttribute("id", "code-annotation-line-highlight-gutter");
              gutterDiv.style.position = 'absolute';
              const codeCell = window.document.getElementById(targetCell);
              const gutter = codeCell.querySelector('.code-annotation-gutter');
              gutter.appendChild(gutterDiv);
            }
            gutterDiv.style.top = top - 2 + "px";
            gutterDiv.style.height = height + 4 + "px";
          }
          selectedAnnoteEl = annoteEl;
        }
      };
      const unselectCodeLines = () => {
        const elementsIds = ["code-annotation-line-highlight", "code-annotation-line-highlight-gutter"];
        elementsIds.forEach((elId) => {
          const div = window.document.getElementById(elId);
          if (div) {
            div.remove();
          }
        });
        selectedAnnoteEl = undefined;
      };
        // Handle positioning of the toggle
    window.addEventListener(
      "resize",
      throttle(() => {
        elRect = undefined;
        if (selectedAnnoteEl) {
          selectCodeLines(selectedAnnoteEl);
        }
      }, 10)
    );
    function throttle(fn, ms) {
    let throttle = false;
    let timer;
      return (...args) => {
        if(!throttle) { // first call gets through
            fn.apply(this, args);
            throttle = true;
        } else { // all the others get throttled
            if(timer) clearTimeout(timer); // cancel #2
            timer = setTimeout(() => {
              fn.apply(this, args);
              timer = throttle = false;
            }, ms);
        }
      };
    }
      // Attach click handler to the DT
      const annoteDls = window.document.querySelectorAll('dt[data-target-cell]');
      for (const annoteDlNode of annoteDls) {
        annoteDlNode.addEventListener('click', (event) => {
          const clickedEl = event.target;
          if (clickedEl !== selectedAnnoteEl) {
            unselectCodeLines();
            const activeEl = window.document.querySelector('dt[data-target-cell].code-annotation-active');
            if (activeEl) {
              activeEl.classList.remove('code-annotation-active');
            }
            selectCodeLines(clickedEl);
            clickedEl.classList.add('code-annotation-active');
          } else {
            // Unselect the line
            unselectCodeLines();
            clickedEl.classList.remove('code-annotation-active');
          }
        });
      }
  const findCites = (el) => {
    const parentEl = el.parentElement;
    if (parentEl) {
      const cites = parentEl.dataset.cites;
      if (cites) {
        return {
          el,
          cites: cites.split(' ')
        };
      } else {
        return findCites(el.parentElement)
      }
    } else {
      return undefined;
    }
  };
  var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
  for (var i=0; i<bibliorefs.length; i++) {
    const ref = bibliorefs[i];
    const citeInfo = findCites(ref);
    if (citeInfo) {
      tippyHover(citeInfo.el, function() {
        var popup = window.document.createElement('div');
        citeInfo.cites.forEach(function(cite) {
          var citeDiv = window.document.createElement('div');
          citeDiv.classList.add('hanging-indent');
          citeDiv.classList.add('csl-entry');
          var biblioDiv = window.document.getElementById('ref-' + cite);
          if (biblioDiv) {
            citeDiv.innerHTML = biblioDiv.innerHTML;
          }
          popup.appendChild(citeDiv);
        });
        return popup.innerHTML;
      });
    }
  }
});
</script>
</div> <!-- /content -->
<footer class="footer"><div class="nav-footer"><div class="nav-footer-center"><div class="toc-actions d-sm-block d-md-none"><ul><li><a href="https://github.com/pythonhealthdatascience/stars-eom-rcc/edit/main/pages/model_overview.qmd" class="toc-action"><i class="bi bi-github"></i>Edit this page</a></li><li><a href="https://github.com/pythonhealthdatascience/stars-eom-rcc/issues/new" class="toc-action"><i class="bi empty"></i>Report an issue</a></li></ul></div></div></div></footer><script>var lightboxQuarto = GLightbox({"openEffect":"zoom","selector":".lightbox","descPosition":"bottom","loop":false,"closeEffect":"zoom"});
(function() {
  let previousOnload = window.onload;
  window.onload = () => {
    if (previousOnload) {
      previousOnload();
    }
    lightboxQuarto.on('slide_before_load', (data) => {
      const { slideIndex, slideNode, slideConfig, player, trigger } = data;
      const href = trigger.getAttribute('href');
      if (href !== null) {
        const imgEl = window.document.querySelector(`a[href="${href}"] img`);
        if (imgEl !== null) {
          const srcAttr = imgEl.getAttribute("src");
          if (srcAttr && srcAttr.startsWith("data:")) {
            slideConfig.href = srcAttr;
          }
        }
      } 
    });
  
    lightboxQuarto.on('slide_after_load', (data) => {
      const { slideIndex, slideNode, slideConfig, player, trigger } = data;
      if (window.Quarto?.typesetMath) {
        window.Quarto.typesetMath(slideNode);
      }
    });
  
  };
  
})();
          </script>




</body></html>